Share Name Share Symbol Market Type Share ISIN Share Description
Hutchmed (china) Limited LSE:HCM London Ordinary Share KYG4672N1198 ORD USD0.10
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  3.00 0.51% 595.00 591.00 594.00 615.00 583.00 595.00 391,252 16:35:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 166.7 -138.8 -13.2 - 4,430

Hutchmed (China) Limited HUTCHMED to Attend Upcoming Investor Conferences

07/05/2021 12:00pm

RNS Non-Regulatory


Hutchmed (China) Limited

07 May 2021

Press Release

HUTCHMED to Attend Upcoming Investor Conferences

Hong Kong, Shanghai & Florham Park, NJ - Friday, May 7, 2021: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM) today announces that Mr Christian Hogg, Chief Executive Officer of HUTCHMED, will participate in a virtual fireside chat at the Bank of America 2021 Health Care Conference on Tuesday, May 11, 2021 at 8:00 a.m. Eastern Daylight Time (EDT).

The discussion will be webcast live and can be accessed at Investors interested in listening to the live webcast should log on before the start time to download any software required. A replay of the event will be available shortly thereafter for approximately 90 days.

Members of the senior management team will also attend virtual one-on-one meetings at the Bank of America Health Care Conference, as well as during the following other conferences:

   --      MS Virtual Asia Healthcare Conference from Thursday to Friday, May 13 to 14, 2021; 
   --      Jefferies Virtual Global Healthcare Conference from Tuesday to Friday, June 1 to 4, 2021; 
   --      Citi Pan-Asia Regional Investor Conference from Wednesday to Friday, June 2 to 4, 2021; and 

-- Goldman Sachs Global Healthcare Conference Webcast from Tuesday to Friday, June 8 to 11, 2021.


HUTCHMED (Nasdaq/AIM: HCM) (formerly Hutchison China MediTech) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. A dedicated organization of over 1,200 personnel has advanced ten cancer drug candidates from in-house discovery into clinical studies around the world, with its first two oncology drugs now approved and launched. For more information, please visit: or follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED's filings with the U.S. Securities and Exchange Commission and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.


Investor Enquiries 
  Mark Lee, Senior Vice President     +852 2121 8200 
  Annie Cheng, Vice President         +1 (973) 567 3786 
Media Enquiries 
  Americas - Brad Miles,              +1 (917) 570 7340 (Mobile) 
   Solebury Trout             
  Europe - Ben Atwell / Alex Shaw,    +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) 
   FTI Consulting             
  Asia - Joseph Chi Lo / Zhou Yi,     +852 9850 5033 (Mobile) / +852 97 83 6894 (Mobile) 
Nominated Advisor 
  Freddy Crossley / Atholl Tweedie, 
   Panmure Gordon (UK) Limited        +44 (20) 7886 2500 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

May 07, 2021 07:00 ET (11:00 GMT)

1 Year Hutchmed (china) Chart

1 Year Hutchmed (china) Chart

1 Month Hutchmed (china) Chart

1 Month Hutchmed (china) Chart
ADVFN Advertorial
Your Recent History
Hutchmed (..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210802 03:00:13